Intelligence / Healthtech / FDA 510(k) Clearances / bioMérieux, Inc.
Approvalsdevice cleared3 Nov 2026
bioMérieux, Inc.
3 Nov 2026: Device cleared · VITEK PRO. Recorded in the openFDA device 510(k) data.
- Decided
- 3 Nov 2026
- Device
- VITEK PRO
- Specialty
- Microbiology
- Country
- United States
- Location
- Hazelwood, MO
- Clearance type
- Traditional
- 510(k) number
- K262683
- Submitted
- 2026-07-31
What this signal means
A clearance starts commercialisation: distribution, reimbursement, software and sales hires.
- 268 added in the 30 days to 9 Nov 2026.
- Cardiovascular leads with 122 clearances, then Radiology (107).
Reach them with AOS
Find the decision makers at bioMérieux, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for bioMérieux, Inc. in our registers.
4 NovBIOMERIEUX, Inc.device cleared · HealthtechApprovals1 OctbioMerieux, Inc.device cleared · HealthtechApprovals28 SeptBiomérieux, Inc.device cleared · HealthtechApprovals4 NovBiomerieux SAClass II recall · HealthtechQuality30 SeptBiomerieux INCClass II recall · HealthtechQuality
More in Microbiology
FDA 510(k) Clearances
6 NovBiofire Diagnostics, LLCdevice cleared · BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel; BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel MidApprovals4 NovBioFire Defense, LLCdevice cleared · BioFire Warrior Panel Control KitApprovals4 NovBIOMERIEUX, Inc.device cleared · VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 >=16µg/mL)Approvals4 NovMolecular Designsdevice cleared · SimplicityDx Panel FluA/FluB/RSVApprovals30 OctGenMark Diagnostics, Inc.device cleared · cobas eplex respiratory pathogen panel 3Approvals30 OctMaine Molecular Quality Controls, Inc.device cleared · eplex RP3 Control M530; eplex RP3 NegativeApprovals
Source: openFDA device 510(k) data, data to 9 Nov 2026. Devices FDA found substantially equivalent and cleared for the US market. Decision dates as published by FDA. AOS shows what the public record says; it does not verify or endorse the company.